Navigation Links
Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
Date:4/23/2008

uating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or IV metastatic melanoma. Based on advice from clinical experts and detailed guidance received from the U.S. Food and Drug Administration (FDA) in an End-of-Phase 2 meeting, Vical successfully completed a Special Protocol Assessment (SPA) with the FDA for a Phase 3 trial (the Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma, or AIMM trial) for certain patients with Stage III or Stage IV melanoma. The SPA agreement specifies that the trial design and planned analyses address the study's objectives and the resulting study data could provide the primary basis to support a product license application.

Allovectin-7(R) has been granted orphan drug designation for the treatment of invasive and metastatic melanoma by the FDA's Office of Orphan Products Development. Orphan drug designation provides U.S. marketing exclusivity for seven years if marketing approval is received from the FDA, in addition to certain tax benefits for qualifying expenses.

Patients featured in the video report were selected from complete responders in earlier trials, and do not represent the majority. In the Phase 2 study, the overall response rate was 11.8%, including 11 partial responders and 4 complete responders from the 127 patients treated. The drug-related side effects in the Phase 2 study were predominantly mild and temporary, including pain and inflammation at the injection site and flu-like symptoms such as fatigue, fever, muscle and joint pain, and headache.

About the AIMM Trial

In early 2007, Vical initiated a Phase 3 pivotal trial of the company's Allovectin-7(R) cancer immunotherapeutic as first-line therapy in chemotherapy-naive patients with Stage III or IV metastatic melanoma. The AIMM trial is being conducted in accordance with the SPA agreement at more than 60 clinical sites, and is currently enrolling patients in the United States, Canada and Europe. AnGes M
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... Md., Jan. 31, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... a universal shelf registration statement on Form S-3 with ... effective by the SEC, the shelf registration statement will ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it will report its unaudited financial results ... before the U.S. market opens on February 18, 2011. ... 2011. The Company,s senior management will ...
Cached Medicine Technology:Vanda Pharmaceuticals Files Shelf Registration Statement 2Vanda Pharmaceuticals Files Shelf Registration Statement 3Vanda Pharmaceuticals Files Shelf Registration Statement 4China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
(Date:8/28/2015)... ... 2015 , ... Approximately 2,000 United Methodists are expected to ... children, a thank you to the many creative and generous ways in which ... Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium event, ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th by ... has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from ... several months, but the current process, having already gone on for over a year, ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, ... as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. Held ... was to raise money to support music education programs in the underfunded local school ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... 16, 2009 A new study published in ... almost twice as high in people with epilepsy compared ... minorities have seven times the odds of depression in ... show that 40 percent of depressed respondents with epilepsy ...
... test capable of confirming or ruling out Alzheimer,s disease ... University of Pennsylvania School of Medicine. By measuring cerebrospinal ... hallmarks amyloid beta42 peptide and tau protein ... impairment would convert to Alzheimer,s disease over time. Researchers ...
... proudly announces that the Peyton Manning Children,s Hospital at ... 6th Annual Talk Walk Run 2009 fundraiser benefiting deaf ... more than 30 years, Hear Indiana has helped children ... members of society," said R. Christopher Miyamoto, pediatric ENT ...
... Will Deliver Educational Training and Professional Certification ... PulseLearning, a leading Ireland-based provider of ... to develop customized eLearning and certification programs ... Casualty Underwriters and the Insurance Institute of ...
... 16 OrbusNeich Medical, Inc. ("Orbus" or the "Company"), ... devices for the treatment of vascular diseases, today announced ... Corporation ("BSC"). The lawsuit, filed in the United ... asserts claims against BSC for patent infringement, breach of ...
... a novel genetic technology that covers up genetic errors, ... Health have developed a successful treatment for dogs with ... and ultimately fatal, muscle disease. , The technology, known ... as molecular "patches." These patches cover up mutant DNA ...
Cached Medicine News:Health News:Depression twice as likely in seizure sufferers 2Health News:Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimer's disease 2Health News:Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimer's disease 3Health News:Peyton Manning Children's Hospital at St. Vincent Will Serve As Lead Sponsor of Hear Indiana's 6th Annual Talk Walk Run 2009 2Health News:Ireland's PulseLearning Inks Agreement With Leading U.S. Insurance Industry Association 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 3Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 2Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 3
The IgA in vitro diagnostic enzyme immunoassay is intended for the qualitative detection of anti-human tTG IgA antibodies in human serum as an aid in the diagnosis of CD....
...
... The FIDIS system and its ... simultaneously and on the same sample, ... dedicated to all types of laboratories ... than today their daily routine, as ...
The PICO50 is used for arterial line sampling....
Medicine Products: